Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Dermira, Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States. The company?s late-stage product candidates comprise Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor, which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04, a anticholinergic product that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01, a sebum inhibitor, which has completed a Phase IIa clinical trial for the treatment of acne. Its early-stage programs in preclinical development include DRM02, an inhibitor of phosphodiesterase-4 for the treatment of inflammatory skin diseases; and DRM05, a photodynamic therapy for the treatment of acne. Dermira, Inc. has a collaboration agreement with UCB Pharma S.A. for the development and commercialization of Cimzia. The company was formerly known
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-17.27%||ROE||-20.31%||ROI|
|Current Ratio||10.38||Quick Ratio||Long Term Debt/Equity||0.02||Debt Ratio||0.09|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||40 K||Cash From Investing Activities||1.86 M||Cash From Operating Activities||-5.12 M||Gross Profit|
|Net Profit||-14.04 M||Operating Profit||-14.23 M||Total Assets||165.61 M||Total Current Assets||124.49 M|
|Total Current Liabilities||12 M||Total Debt||1.94 M||Total Liabilities||24.75 M||Total Revenue|
|High 52 week||14.82||Low 52 week||5.31||Last close||5.31||Last change||0%|
|RSI||18.73||Average true range||0.46||Beta||1.1||Volume||98.87 K|
|Simple moving average 20 days||-18.35%||Simple moving average 50 days||-30.51%||Simple moving average 200 days||-40.72%|
|Performance Week||-7.17%||Performance Month||-40.67%||Performance Quart||-38.04%||Performance Half||-55.27%|
|Performance Year||-54.54%||Performance Year-to-date||-26.15%||Volatility daily||3.7%||Volatility weekly||8.28%|
|Volatility monthly||16.97%||Volatility yearly||58.78%||Relative Volume||231.19%||Average Volume||645.15 K|
|New High||New Low|
2020-02-23 17:23:01 | Largest Insider Trades of the Week
2020-02-20 08:55:00 | Lilly Completes Acquisition of Dermira
2020-01-30 10:38:03 | Lilly LLY Q4 Earnings and Sales Top Estimates, Stock Up
2020-01-30 10:08:15 | Eli Lilly beats profit estimates on strong demand for diabetes drug Trulicity
2020-01-29 19:26:00 | Lifshitz & Miller LLP Announces Investigation of AquaVenture Holdings Limited, CenterState Bank Corporation, Dermira, Inc., The Habit Restaurants, Inc., Hexcel Corporation, LogMeIn, Inc., Telaria, Inc, and TiVo Corporation
2020-01-27 08:16:01 | Lilly LLY to Report Q4 Earnings: What's in the Cards?
2020-01-16 18:23:54 | Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO
2020-01-15 13:19:00 | Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Dermira, Primo Water, Hexcel, and Pope Resources on behalf of Stockholders and Encourages Investors to Contact the Firm
2020-01-15 11:16:00 | Moore Kuehn, PLLC Encourages PRMW, DERM, CBB, and HABT Investors to Contact Firm
2020-01-14 11:13:00 | Big Merger Deals Are Missing at Health Conference. Here’s Why.
2020-01-13 12:33:31 | Biotech Stocks Slip on Lack of Deals at JPMorgan Conference
2020-01-13 09:08:02 | Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate
2020-01-10 18:00:38 | Biotechs punch up talking points leading into big Union Square conference
2020-01-10 15:23:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Dermira, Inc.
2020-01-10 12:28:24 | DERMIRA MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dermira, Inc. is Fair to Shareholders; Investors are Encouraged to Contact the Firm – DERM
2020-01-10 12:13:00 | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dermira, Inc.
2020-01-10 10:43:55 | Eli Lilly to add eczema drug with $1.1 billion deal for Dermira
2020-01-10 10:43:07 | Eli Lilly, Apple, Yum! Brands, Nintendo: Companies to watch
2020-01-10 09:50:00 | Lilly Says It’s Buying a Biotech With a Dermatitis Drug. Investors Have Other Ideas.
2020-01-10 09:03:08 | Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR
2020-01-10 07:28:30 | Eli Lilly Reports Deal To Buy Dermira For $1.1B
2020-01-10 06:42:00 | Eli Lilly to buy Dermira in a deal valued at $1.1 billion
2020-01-10 06:30:00 | Lilly Announces Agreement to Acquire Dermira
2020-01-10 04:44:00 | Eli Lilly to Buy Skin Treatment Company Dermira for $1.1 Billion
2020-01-10 03:38:00 | Pre-market Movers - Eli Lilley, Boeing in View
2020-01-09 06:19:11 | Buy Multibagger Stocks as Odds of a Rally Are High in 2020
2020-01-08 11:16:04 | Pacira's PCRX Exparel Meets Key Goals in C-Section Study
2020-01-06 10:00:03 | Moving Average Crossover Alert: Dermira
2020-01-06 07:31:12 | Will Dermira Continue to Surge Higher?
2019-12-19 17:51:03 | 4 More Biotechs With Blockbuster Potential
2019-12-10 16:05:00 | Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635c4